

# Cowboy Joe Philips



September 10, 2005



82 year old cowboy who came to me mid September 2003 after being diagnosed with:

**pancreatic, liver, stomach, throat and neck cancer**  
so severe that there were no treatments offered

In addition to testing, his CA19-9 cancer marker was about 800, where below 33 is normal, by January 2004, it was 310, by Nov 2004, it is "11". In September 2003, doctors told him to go home and call hospice, he was told he had between 3 months and 3 years to live. Basically, the first time frame (3 months) is what doctors truly believe is accurate, second timeframe (3 years ) is what they tell the patient so that they do not get depressed or have a heart attack over the first time-frame. As of Nov. 24, 2004, he showed no evidence of cancer anywhere in his body.

In late 2005, Joe had a Brown Recluse Spider bite while in Pennsylvania, a huge welt on his foot. Local doctors ignored the welt, assumed it as recurrent cancer. Left untreated, the venom caused kidney failure, additional tests indicated "No evidence of cancer", his cancer marker was also at "7" up to "34" is normal – no cancer evident. He passed away on March 15, 2006 at the age of 82. Joe was a wonderful man of great inspiration and drive and kindness. We miss him terribly.



PATIENT: , JOSEPH

DOCTOR: RUTH DIAZ, M.D.  
1 RABRO DRIVE  
HAUPPAUGE NY 11788

REPORT NUMBER		ACCOUNT NUMBER	REPORT STATUS	
Q0087254		13144	FINAL	
DATE COLLECTED		DATE RECEIVED	DATE REPORTED	
01/09/2004		01/10/2004	01/14/2004	
AGE	SEX	AREA	ROUTE	PAGE
80	M	200		3

TEST NAME	WITHIN REF. RANGE	OUTSIDE REF. RANGE	LAB REF. RANGE	UNITS
-----------	-------------------	--------------------	----------------	-------

CA 19-9 *\* advanced cancer* → 310 ↑ H M <33.0 UNITS/ML

Test manufacturer: Diagnostic Products Corp.  
Test methodology: EIA

Values obtained with different assay methods cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

\*\* Note Reference Range Change as of 8/21/03

CEA 1.6 0-5.0 NG/ML

Test manufacturer: Diagnostic Products Corp..  
Test methodology: EIA

Values obtained with different assay methods cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

PROSTATIC SPECIFIC ANTIGEN  
PSA 12.70 *13.9* H 0-4.0 NG/ML

Test manufacturer: Diagnostic Products Corp.  
Test methodology: EIA

Values obtained with different assay methods cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

PSA FREE AND TOTAL  
PSA 12.70 H 0-4.0 NG/ML

Test manufacturer: Diagnostic Products Corp.  
Test methodology: EIA

Values obtained with different assay methods cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

PSA, FREE 2.58 see below NG/ML  
PSA, % FREE 20.3 see below %

Percent free PSA is used to determine risk of prostate cancer;  
REPORT CONTINUED ON NEXT PAGE

ANNE B. PLATT, M.D. MEDICAL DIRECTOR & PATHOLOGIST

*This is 1/9/2004 Report*



ACCOUNT NUMBER  
10161

REFERRING PHYSICIAN/ACCOUNT



Laboratory Locations:  
 Long Island 60 Executive Blvd.  
 Farmingdale, NY 11735  
 Manhattan 157 East 81st Street  
 New York, NY 10028  
 New Jersey (Office) One West Ridgewood Ave.  
 Paramus, NJ 07652  
 Client Services 1-800-371-5227  
 Lab 1-800-522-5052

REPORT STATUS  
FINAL

ACCESSION NUMBER

Q4314861

PATIENT INFORMATION

JOSEPH

ROUTE	AREA	DATE COLLECTED	DATE RECEIVED	DATE REPORTED	SEX	AGE	PAGE
	999	11/27/2004 9:05 AM	11/27/2004 7:20 PM	11/30/2004 6:09 AM	M	81	2

Notes:

TESTS	RESULTS	REFERENCE VALUES
THE CONTROL VALUE FOR PTT HAS BEEN ESTABLISHED TO BE THE MID-POINT OF THE NORMAL RANGE (31.5 SECONDS).		
CONTROL	31.5	SEC.
HEPATIC PANEL		
PROTEIN TOTAL	7.2	6.4-8.0 G/DL
ALBUMIN	3.9	3.7-4.9 G/DL
GLOBULIN	3.3	2.1-3.7 G/DL
A/G RATIO	1.2	1.0-2.0 RATIO
BILIRUBIN TOTAL	0.5	0.3-1.6 MG/DL
AST (SGOT)	14	12-48 IU/L
ALT (SGPT)	13	7-50 IU/L
ALKALINE PHOS	121	25-130 IU/L
AMYLASE	110	25-125 U/L
GGT	20	11-94 IU/L
LIPASE	79	7.00-60.0 UNITS/L
CA 19-9	11	<19.0 UNITS/ML

Test manufacturer: Diagnostic Products Corp.

Test methodology: EIA

Values obtained with different assay methods cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

TYPE &amp; RH

TYPE

Rh FACTOR

B

POSITIVE

FINAL REPORT

Indicates no evidence of cancer  
 when below 19 he is at 11  
 he was at 382

Medical Director  
Anne B. Platt, M.D.

PATIENT DIAGNOSED ON  
 SEPT 2003 WITH:  
 Pancreatic, Liver, Stomach,  
 Throat and Neck cancer

Date: 11/27/04

BER



REPORT STATUS

Final

REFERRING PHYSICIAN/ACCOUNT

H DIAZ, M.D.  
Rabro Drive  
Hauppauge, NY 11788  
631-234-7878

Laboratory Locations:

Long Island 60 Executive Blvd.  
Farmingdale, NY 11735  
Manhattan 157 East 81st Street  
New York, NY 10028  
New Jersey (Office) One West Ridgewood Ave.  
Paramus, NJ 07652  
Client Services 1-800-371-5227  
Lab 1-800-522-5052

ACCESSION NUMBER

R3786339 Req: 1576ED207

PATIENT INFORMATION

, JOSEPH A  
101147074  
631-732-7473

ROUTE	AREA	DATE COLLECTED	DATE RECEIVED	DATE REPORTED	SEX	AGE	PAGE
S/ED275		09/16/2005 07:28	09/16/2005 23:09	09/22/2005 14:10	M	82	4

Report Previously Issued on 09/17/2005 07:33

Notes: FASTING

TESTS	RESULTS	REFERENCE VALUES
-------	---------	------------------

CA 19-9 9.9 *↓ 14.9* <35.0 U/mL

Test manufacturer: Bayer  
Test methodology: CIA

Values obtained with different assay methods cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

\*\*\* CARCINOEMBRYONIC ANTIGEN \*\*\*

CEA ABBOTT-AXSYM 1.5 0.0-2.5 ng/mL

Test manufacturer: Bayer  
Test methodology: CIA

Values obtained with different assay methods cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

\*\*\* PSA, FREE \*\*\*

PSA 12.60<H> 0-4.0 (*Same*) NG/ML

Test manufacturer: Diagnostic Products Corp.  
Test methodology: EIA

Values obtained with different assay methods cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.


PSA, FREE 2.63 see below NG/ML

CONTINUED ON NEXT PAGE

Medical Director  
Anne B. Platt, M.D.



# PET Scan - January 12, 2004



# PET Scan March 18, 2004

